Search clinical trials for: RPN301

Total 39 results

HK inno.N Corporation

Completed

Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301

Parenteral Nutrition

Korea, Republic of
Reneo Pharma Ltd

Completed

A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

Fatty Acid Oxidation Disorders

United States, France, Spain
Yung Shin Pharm. Ind. Co., Ltd.
Changhua Christian Hospital

Completed

A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis

Herpes Labialis

Taiwan
HK inno.N Corporation

Completed

Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301

Parenteral Nutrition

Korea, Republic of
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Recurrent Colorectal Carcinoma | Unresectable Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Solid Neoplasm | Recurrent Solid Neoplasm | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic... and other conditions

United States
Reneo Pharma Ltd

Terminated

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Primary Mitochondrial Myopathy

Spain, Australia, Belgium, Denmark, Canada, United Kingdom, France, Germany, Hungary, Italy, Netherlands, New Zealand
Reneo Pharma Ltd

Completed

A Study of the Safety of REN001 in Patients With McArdle Disease

McArdle Disease

Spain, United Kingdom
Reneo Pharma Ltd

Terminated

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Primary Mitochondrial Myopathy

United Kingdom
Regenera Pharma Ltd

Completed

Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

Non-arteritic Ischemic Optic Neuropathy | Optic Nerve Injuries

Israel
Hadassah Medical Organization

Withdrawn

The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements (CVS)

Chronic Vegetative State
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Melanoma | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IIIA Melanoma | Stage IIIB Melanoma and other conditions

United States
Reneo Pharma Ltd

Completed

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients (STRIDE)

Primary Mitochondrial Myopathy

United States, Spain, Australia, France, United Kingdom, New Zealand, Denmark, Norway, Czechia, Belgium, Canada, Germany, Hungary, Italy, Netherlands
Regenera Pharma Ltd

Withdrawn

Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn

Partial Thickness Burn | Second Degree Burn Less Than 5%TBSA

Israel
Alebund Pty Ltd

Completed

A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

Healthy Subjects

Australia
Regenera Pharma Ltd

Completed

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

Mild to Moderate Dementia Due to Alzheimer's Disease | With or Without Coexisting Cerebrovascular Disease

Canada
Regenera Pharma Ltd
TransCom Global Ltd. (CRO)

Terminated

Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds

Chronic Wound

Israel
invIOs GmbH

Recruiting

PBMC-based Leukocyte Immunotherapy (PALINDROM)

Advanced Solid Tumor

Austria
Columbia University
TG Therapeutics, Inc.

Terminated

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Regenera Pharma Ltd
Syneos Health

Completed

A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease

Healthy Volunteers | Moderate to Severe Alzheimer Patients

Canada
Speedel Pharma Ltd.

Terminated

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

Diabetic Nephropathy

United States
Conjupro Biotherapeutics, Inc.

Recruiting

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Cancer | Cancer, Lung

Canada, United States
Apeiron Biologics

Completed

Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer

Radiation Induced Dermatitis

Austria
Radiopharm Theranostics, Ltd

Recruiting

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer

Healthy Volunteers | Pancreatic Ductal Adenocarcinoma

United States
Regenera Pharma Ltd

Terminated

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Nonarteritic Anterior Ischemic Optic Neuropathy

United States
Hadassah Medical Organization

Suspended

The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study (RPh-in-CVS)

Chronic Vegetative State

Israel
Virtuoso BINco, Inc.

Terminated

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

Lymphoma | Multiple Myeloma | Solid Tumors, Adult

United States
Apeiron Biologics

Completed

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)

COVID-19

Denmark, Germany, Austria, Russian Federation, United Kingdom
BioNova Pharmaceuticals (Shanghai) LTD.

Terminated

Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Migraine | Major Depressive Disorder

United States, Czechia, Finland, Israel, Italy, Russian Federation, Spain, Ukraine, France, Germany, Greece, Poland, United Kingdom
Apeptico Forschung und Entwicklung GmbH

Completed

Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

Acute Lung Injury

Austria
Wellstat Therapeutics

Approved for marketing

Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination

Toxicity Due to Chemotherapy
Wellstat Therapeutics

Completed

Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria

Hereditary Orotic Aciduria

United States
Apeiron Biologics

Completed

Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)

Cardiovascular Diseases | Kidney Diseases | Pulmonary Diseases | Cancer Diseases

Switzerland
Apeptico Forschung und Entwicklung GmbH

Recruiting

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

ARDS

Austria, Germany
TRPHARM

Withdrawn

Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator

Healthy
Redwood Pharma AB
Cross Research S.A.

Completed

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Dry Eye Syndromes

Austria, Germany, Hungary
SciClone Pharmaceuticals

Terminated

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine (RP101)

Pancreatic Cancer

United States, Chile, Spain, Brazil, Argentina, France, Germany, Hungary, Netherlands, Peru, Poland, Romania, United Kingdom
PharmaNeuroBoost N.V.

Completed

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

Major Depressive Disorder

United States, Canada
Ipsen

Terminated

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Neuroendocrine Tumors

United States, Australia, Austria, Canada, Denmark, France, Switzerland, United Kingdom

Search clinical trials for: RPN301

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations